Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSTP1 polymorphism and response to aggressive cyclophosphamide therapy in lupus nephritis
TCTR20180828012Completed
- Sponsor
- Self
- Start
- Jan 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of cyclophosphamide in lupus nephritis (LN) and systemic lupus erythematosus (SLE) (2 arms), sponsored by Self. Primary endpoints: GSTP1 polymorphism status, Treatment response or remission and 2 more. Started Jan 2016; status: completed.
02
Drugs
cyclophosphamide
03
Conditions
lupus nephritis (LN)systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on TCTR20180828012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20180828012.